Sanofi has appointed Gary Nabel as senior vice president, chief scientific officer and deputy to the president for global r&d, effective from 3 December. He will report to Elias Zerhouni, president, global r&d, and join the group’s Global Leadership Team. He will be based in Cambridge, MA, US.
Nabel joins Sanofi from the National Institutes of Health, where was director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases from 1999.
‘Dr Nabel's impressive scientific record and experience will be extremely valuable to the Group,’ said Christopher Viehbacher, chief executive of Sanofi. ‘I am confident that with his leadership, we can drive r&d further towards tomorrow’s breakthrough discoveries.’
In his new position, Nabel will be responsible for assessing and coordinating Sanofi’s scientific direction for biopharmaceuticals, vaccines and animal health with a focus on improving translational approaches across Sanofi. In his role, he will lead the evaluation of scientific quality of projects and programs across all of R&D, and participate in setting Sanofi’s overall strategy.’
